Bryan Johnson, the 48-year-old Silicon Valley entrepreneur who built an empire around the idea that death is optional, has disclosed a diagnosis that his million-dollar medical machine failed to catch for over a decade. Johnson announced he has autoimmune gastritis, a condition with no approved cure, even as he runs what may be the most expensive personal health program on the planet.
The man who tracks his erections, injects his teenage son's plasma into his veins, and submits to regular colonoscopies and MRIs as part of a $1 million-per-year longevity regimen called "Immortals Care" did not know his stomach lining was destroying itself. He had unexplained low ferritin levels for eleven years. Nobody on his team connected the dots until May, when a stomach biopsy finally confirmed the diagnosis.
"My stomach is eating itself," Johnson wrote.
Autoimmune gastritis, or AIG, occurs when the body's immune system attacks the cells lining the stomach. The charity Guts UK defines it as "inflammation in the stomach caused by the body's cells attacking its own tissues." It leads to nutrient deficiency, anemia, and a potentially elevated risk of stomach cancer. There is no cure. The condition is typically asymptomatic until significant damage has already been done.
Johnson discovered the diagnosis only after a complete overhaul of his medical team. A series of tests, including an examination of his intestinal tract, revealed elevated anti-parietal-cell antibodies. The stomach biopsy confirmed what the bloodwork suggested.
For context, Johnson was diagnosed with hypothyroidism at age 21 and managed it with standard treatments for nearly three decades. Guts UK notes that autoimmune gastritis "occurs more often in people who have other autoimmune diseases like thyroid disease." The connection between the two conditions was, apparently, not flagged by any of the specialists Johnson employed over the years, despite the persistent iron problem staring them in the face.
As Johnson himself explained, the two conditions reinforce each other. He told followers that "iron and thyroid feed each other both ways, low iron impairs the conversion of thyroid hormone into its active form and an underactive thyroid impairs how the body uses iron." That feedback loop ran unchecked for over a decade while Johnson spent $2 million annually on his health.
Johnson is not a fringe figure. He burst into the public eye in 2023, earned the informal title of the biohacking movement's "godfather," and starred in the Netflix documentary Don't Die: The Man Who Wants to Live Forever. In that film, he controversially revealed the plasma injections from his teenage son. His daily routine includes fat injections, blood transfusions, regular imaging, a strict diet, and a rigid sleep schedule.
None of it caught the autoimmune process silently eating his stomach lining.
Johnson attributed the root cause to years of high-stress work as CEO of the fintech company Braintree, a period he said left him in "a deep, chronic depression." In his youth, he routinely ate fast food and sugary drinks. He framed the diagnosis as the consequence of damage accumulated long before his biohacking crusade began.
"Somewhere in that timeline, my body began developing an autoimmune process affecting my thyroid and then my stomach lining."
That explanation may be accurate. But it also raises a harder question: if a man spending seven figures a year on cutting-edge diagnostics cannot detect a common autoimmune condition for eleven years, what exactly is the product he is selling?
Johnson is not accepting the diagnosis quietly. He stated that his team's attempt to cure AIG "will be a world first." He invoked artificial intelligence, multiomics, and custom-built DNA, proteins, and cells as tools that might succeed where conventional medicine has not.
"When AIG is discovered today, standard medical care concedes defeat, stating that nothing can be done except managing the condition, no matter how awful or lethal the effects."
He followed that with a broader declaration, posted on X:
"I don't intend to live a little. I intend to live more than any human who has yet lived and invite you to join."
The ambition is characteristically grand. But Johnson has not specified what experimental interventions his team plans to deploy. No treatment protocol has been named. No timeline has been offered beyond monitoring iron levels and performing additional tests. The promise of a "world first" cure rests, for now, entirely on Johnson's word.
Even the basic prevalence figures Johnson cited don't align cleanly with the medical sources his own announcement referenced. Johnson stated AIG affects "two to five per cent of people", which translates to 20 to 50 out of every 1,000. Guts UK, cited in the same reporting, estimates the figure at 5 to 20 per 1,000. The upper end of Johnson's range is more than double the upper end of Guts UK's estimate. Neither figure was reconciled.
It is a small discrepancy. But for a man whose brand depends on scientific precision, who measures everything from blood markers to sleep cycles to biological age, a casual misstatement about the prevalence of his own diagnosis is worth noting.
Johnson's story is, at bottom, a cautionary tale dressed up in Silicon Valley optimism. He spent more on personal health care in a single year than most American families earn in two decades. He employed a rotating cast of specialists. He submitted to tests that most people will never undergo. And the result was an eleven-year diagnostic blind spot for a condition that, by his own account, was signaling its presence the entire time through chronically low iron.
AIG is more common in women and the elderly, but it is not exotic. It is not rare in the way that justifies a decade of missed signals from a team billing at that rate. The condition's link to pre-existing thyroid disease is well documented, documented enough that Guts UK flags it in general-audience health materials.
Johnson now promises to throw the full weight of his resources at a cure. Perhaps he will succeed. Perhaps AI-driven medicine will crack what conventional approaches have not. But the fact remains: the most surveilled human body in modern history harbored a destructive autoimmune process for years, and nobody noticed until the team was replaced.
That is not an argument for spending more on biohacking. It is an argument for humility about what money can actually buy.
You can spend $2 million a year trying to outrun mortality. But the body keeps its own books, and it doesn't care how much you paid for the audit.
